Abstract：Objective Analyze the prevalence situation of Diabetic Peripheral Neuropathy in type 2 diabetes mellitus, study the related risk factors and inflammatory factors.Methods From January 2015 to July 2016,according to DPN diagnostic criteria ,the patients were diagnosed as type 2 diabeteswere divided into diabetic peripheral neuropathy group and non group. Respectively,check whether combined with diabetic retinopathy and peripheral vascular disease, then analysis of age, weight, BMI, course of disease,biochemical indicator,meanwhile, analyse single factor of each index, and then Logistic multivariate analysis.Results (1)The prevalence of diabetic peripheral neuropathy in the study population was 65.9%; (2)The number of combined with peripheral vascular disease in the diabetic peripheral neuropathy group(69%) was significantly higher than that in non diabetic peripheral neuropathy group (50%),through the χ2 test,the difference was statistically significant (χ2=5.723,P<0.05); (3)compared with non group,in the analysis of various factors,the HbA1c、LDL-C、IL-6、TNF-α、SIL-2R and disease course of diabetic peripheral neuropathy group was statistically significant (t=2.084~3.407,P<0.05).But there was no statistically significant difference compared to other factors.(4)Logistic multivariate analysis:Course、HbA1c、LDL-C、TNF-α、SIR-2R and combined with peripheral vascular disease are independent risk factors for DPN (OR=0.455~1.655,P<0.05).Conclusions The extension of the disease course, peripheral vascular disease, and blood glucose, blood lipid levels and related inflammatory factors of abnormal, will make diabetic neuropathy exacerbations.
郭杨, 宋晓, 侍晓云, 王莉. 2型糖尿病周围神经病变的危险因素及相关炎性反应因子分析[J]. 武警医学, 2017, 28(3): 283-286.
GUO Yang, SONG Xiao, SHI Xiaoyun, and WANG Li. Risk factors and related inflammatory factors analysis of diabetic peripheral neuropathy in patients with ty. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(3): 283-286.
Vincent A M, Hayes J M, McLean L L, et al. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1[J].Diabetes,2009,58(10):2376-2385.
[6]
Coulson W F. Statin neuropathy[J].Fam Pract,2011,60(4):182-184.
[7]
Chong P H, Boskovich A, Stevkovic N. Statin-associated peripheral neuropathy: review of the literature[J].Pharmacotherapy,2004,24(9):1194-1203.
[8]
Gaist D, Jeppesen U, Andersen M, et al.Statins and risk of polyneuropathy: a case-control study[J].Neurology,2002,58(9):1333-1337.
[9]
Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions[J].Phar Res,2014,80(2):21-35.
[10]
Fromont A, De Seze J, Fleury M C, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor[J].Cytokine,2009,45(2):55-57.
[11]
Barak V, Selmi C, Schlesinger M, et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis[J].Autoimmun,2009,33(3-4):178-182.
[12]
Garcia Ruiz P, Canora L, ebrato J, et al. Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis[J].Med Clin (Barc),2004,122(12):441-443.
[13]
Joshi S V, Tambwekar S R, Khadalia K, et al. Role of inflammatory marker interleukin 6 (IL-6) and insulin in diabetes and diabetic neuropathy [J].Bom Hosp,2008,50(3):466-471.
[14]
Halvatsiotis I, Tsiotra P C, Ikonomidis I, et al. Genetic variation in the adiponectin receptor 2 (ADIPOR2) gene is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes[J].Car Dia,2010,23(2):9-10.
2017, Vol. 28 
